Document is current

Article History

Received: 12 December 2025

Accepted: 28 March 2026

First Online: 21 April 2026

Declarations

:

: The BSRBR-RA study was approved by the North West Multicenter Research Ethics Committee (MREC) in December 2000 (MREC 00/8/53). Informed consent was obtained from patients (or their authorized representative) at enrolment to the BSRBR-RA. The consent to be involved in the BSRBR-RA observational study covers the current AMGEVITA study analyses.

: Not applicable.

: AES, ML, RJ, MB, LK, NA – All authors are full-time employees of Amgen Inc. and hold stock and/or stock options as part of their employment compensation. This manuscript reports on data related to an Amgen product. The authors declare no additional financial or personal conflicts of interest. FH – The author declares the following potential conflicts of interest. The author has served as a consultant for Roche, AbbVie, Genentech, UCB, and Novartis. Honoraria have been received from Roche, UCB, and Novartis. The author has participated in speakers’ bureaus for UCB and Novartis. The author reports no corporate appointments, stock ownership, royalties, grants/research support, or other relevant financial or personal relationships that could influence the work reported in this manuscript. LCC – The author has received grants/research support from AbbVie, Amgen, Celgene, Eli Lilly, Janssen, Novartis, Pfizer and UCB; worked as a paid consultant for AbbVie, Amgen, Bristol Myers Squibb, Celgene, Eli Lilly, Gilead, Galapagos, Janssen, Moonlake, Novartis, Oruka, Pfizer, Sitryx, Takeda and UCB; and has been paid as a speaker for AbbVie, Amgen, Biogen, Celgene, Eli Lilly, Galapagos, Gilead, GSK, Janssen, Medac, Novartis, Pfizer and UCB.